# NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
Canonical URL: https://biopharmsignal.com/news/NXTC/nextcure-and-ligachembio-to-present-trial-in-progress-poster-for-lncb74-a-b7-h4--1ce8cc1e
Ticker: NXTC
Company: NextCure
Source: NextCure
Published: 2025-05-29 20:05 EST
## Summary

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose...

## Article Body
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization

The study is currently enrolling in dose escalation

Poster to be presented June 2, 2025, 1:30 pm-4:30 pm CT

BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The Phase 1 study is evaluating LNCB74 as monotherapy in participants with advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer. The trial includes dose escalation and dose expansion and optimization phases. The study is currently enrolling in dose escalation.

"B7-H4 represents an attractive target for ADC therapy given its high expression in multiple tumor types and limited expression in normal tissues," said Udayan Guha, M.D., Ph.D., chief medical officer of NextCure. "LNCB74 has demonstrated a superior safety profile in preclinical studies and potent anti-tumor activity across multiple models, making it a promising therapeutic candidate for patients with B7-H4-expressing solid tumors."

Details of the presentation are as follows:

Title A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4 Targeted Antibody-Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumor Date and Time : June 2, 2025, 1:30 pm-4:30 pm CT Session : Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Abstract Number : TPS3167

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com
## Recent Company News
- 2026-07-14 10:00 EST — [NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy](https://biopharmsignal.com/news/NXTC/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-il-2-9774b133) — Source: NextCure
- 2026-06-04 12:00 EST — [NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers](https://biopharmsignal.com/news/NXTC/nxtc-announces-replay-available-for-virtual-kol-event-discussing-asco-2026-dose--a8660fb2) — Source: NextCure
- 2026-06-01 12:00 EST — [NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026](https://biopharmsignal.com/news/NXTC/nextcure-presents-positive-sim0505-phase-1-dose-escalation-data-in-patients-with-fb481c8c) — Source: NextCure
- 2026-05-07 20:05 EST — [NextCure Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2026-financial-resul-833f438a) — Source: NextCure
- 2026-05-04 11:05 EST — [NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers](https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-zaiming-initiate-dose-optimization-for-sim0505-cdh6-adc-in--e6572d0c) — Source: NextCure
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)